Abstract: Separators for use with gas turbine engines are disclosed herein. An example cabin bleed system disclosed herein includes a bleed line coupled to a gas turbine engine, a separator defining a cavity fluidly coupled to the bleed line, the separator including a first ring including a first opening fluidly coupled to the cavity. a second ring surrounding the first ring, the second ring including a second opening fluidly coupled to a cabin of an aircraft, and a filter disposed in a fluid pathway extending between the first opening and the second opening.

Abstract: A mask stowage container is provided having a door panel coupled to a box via a securement mechanism, the securement mechanism having a striker having a neck and a protrusion, the striker mounted to the door panel, a holder, the holder including a first retainer and a second retainer, the striker configured to be laterally retained between the first retainer and the second retainer.

Abstract: In certain aspects, the present disclosure relates to T?RII fusion polypeptides comprising a heterologous portion and a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.

Abstract: A turbine engine with a compressor section, a combustion section, and a turbine section in serial flow arrangement along an engine centerline. The combustion section includes a primary combustor liner including an inner liner and an outer liner. A dome wall and a primary dome inlet are located in the dome wall. The outer liner defines at least one opening downstream from the primary dome inlet. A primary combustion chamber and a set of secondary combustors are fluidly coupled to the primary combustion chamber at the at least one opening.

Abstract: In certain aspects, the disclosure provides multispecific binders (e.g., ActRIIA:T?RII heteromultimers comprising an ActRIIA polypeptide and a T?RII polypeptide). The disclosure further provides that such multispecific binders (e.g., ActRIIA:T?RII heteromultimer) may be used to treat various disorders or conditions.

Abstract: An example heterostructure semiconductor for sensing a gas comprises a substrate made of nanosheets of a compound of a first metal, wherein the compound of the first metal is sensitive to the gas to be sensed; one or more 1-Dimensional (1D) components fabricated on a surface of the substrate, the 1D components comprising a compound of a second metal, wherein the compound of the second metal is selective to the gas to be sensed; and a 2-Dimensional (2D) layer formed on the surface of the substrate in portions excluding the 1D components, wherein the 2D layer comprises compounds of the first and second metal. Method of fabrication of the heterostructure semiconductor and a chemiresistive sensor made thereof are also disclosed.

Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.

Abstract: A method includes obtaining an indication of a user interface (UI) component of a user interface, and determining an association between the UI component and a dynamic identifier. The method also includes, based on determining the association, determining one or more static properties of one or more parent UI components of the UI component, and generating a component selector for the UI component based on the one or more static properties. The method further includes outputting the component selector for the UI component.

Abstract: The present disclosure pertains to a system and method that enables routing of requests based on active standby routing policy. Prior to routing, the system and method may enable identification/configuration of pair of endpoints pertaining to, for example, an active cluster and a DR cluster. In an example embodiment, the request may be routed to the identified/configured pair if at least one endpoint in the pair may be functional. For example, each endpoint in active cluster may be paired with a corresponding endpoint in the DR cluster to enable routing of request to DR endpoint when the corresponding endpoint in the active cluster may be unavailable. The identification/configuration of pair of endpoints, prior to the routing, may enable effective routing management of the incoming requests.

Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.

Abstract: In some aspects, the disclosure relates to compositions and methods comprising ActRII polypeptides to treat, prevent, or reduce the progression rate and/or severity of pulmonary arterial hypertension, particularly treating, preventing or reducing the progression rate and/or severity of one or more pulmonary arterial hypertension associated complications.

Abstract: The present disclosure pertains to a system that enables hybrid routing with active and standby instances. A request from sites apart from Nagpur site is obtained at 702, and that from Nagpur site is obtained at 706. Then, it is checked at 704, whether any endpoint is active. If so, the request is transmitted to primary cluster 710. However, if no endpoint is active, then at 708, it is checked whether the request is from the Nagpur. If so, then it is checked again, at 712, whether any endpoint is active. However, in case it is found, at the 708, the request is not from Nagpur, then it is fed to Nagpur DR cluster 720. Further, at the 712, if any endpoint is active, then the request is transmitted to Nagpur active cluster 730, but, if no endpoint is active, then the request is fed to DR for Nagpur 740.

Abstract: In some aspects, the disclosure relates to compositions and methods comprising ActRII polypeptides to treat, prevent, or reduce the progression rate and/or severity of post-capillary pulmonary hypertension (PcPH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PcPH-associated complications.

Abstract: Aero-acoustically damped bleed valves are disclosed. An example variable bleed valve apparatus comprises a variable bleed valve door to actuate the variable bleed valve apparatus, and a variable bleed valve port including an upstream edge and a downstream edge, the VBV port to define a secondary flowpath, the VBV door to cover the VBV port in a closed position, and a vortex device at the upstream edge of the variable bleed valve port, the vortex device including a vorticity generating feature along the upstream edge of the variable bleed valve port.

Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of red blood cells or a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.

Abstract: An example described herein is a circuit including a dynamic complementary metal-oxide-semiconductor (CMOS) inverter level translator circuit and a capacitor. The dynamic CMOS inverter level translator circuit is electrically connected to a first power domain and has a first input node configured to receive a first trigger signal generated in the first power domain. The dynamic CMOS inverter level translator circuit has a second input node configured to receive a second trigger signal generated in a second power domain different from the first power domain. The capacitor is electrically coupled to an output node of the dynamic CMOS inverter level translator circuit. The capacitor selectively charges to the first power domain through the dynamic CMOS inverter level translator circuit based on the first trigger signal. The capacitor selectively discharges to provide a negative coupling voltage to a write assist supply node.

Abstract: In some aspects, the disclosure relates to ActRII-ALK4 antagonists and methods of using ActRII-ALK4 antagonists to treat, prevent, or reduce the progression rate and/or severity of heart failure (HF), particularly treating, preventing or reducing the progression rate and/or severity of one or more HF-associated comorbidities. The disclosure also provides methods of using an ActRII-ALK4 antagonist to treat, prevent, or reduce the progression rate and/or severity of heart failure associated with a variety of conditions including, but not limited to, heart failure associated with metabolic complications (e.g., diabetes, obesity).

Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.

Abstract: In part, the present disclosure relates methods for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or one or more complications of a myeloproliferative disorder. The present disclosure further relates methods for treating, preventing, or reducing the severity of a Janus kinase-associated disorder or one or more complications of a Janus kinase-associated disorder. In certain aspects the disclosure provides T?RII antagonists for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or a Janus kinase-associated disorder or one or more complications of a myeloproliferative disorder or a Janus kinase-associated disorder.

Abstract: A gas turbine engine includes a fan section having a plurality of fan blades, the fan section configured to generate an airflow through the gas turbine engine, an airflow passage having a core passage and a bypass passage separate from the core passage, a low-speed shaft coupled to and configured to rotate the plurality of fan blades, and a sensor assembly coupled to the gas turbine engine and configured to detect torsional vibration in the low-speed shaft. The sensor assembly includes a plurality of dynamic pressure sensors in the airflow passage. The plurality of dynamic pressure sensors detect a dynamic pressure of the airflow passage that is indicative of the torsional vibration in the low-speed shaft. A damping system is configured to dampen the torsional vibration in the low-speed shaft based on a correlation of a measured torsional vibration and an experimental torsional vibration.